- Home
- BLK vs GILD Comparison
BLK vs GILD Comparison
Compare BLK & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLK
- GILD
- Stock Information
- Founded
- BLK 1988
- GILD 1987
- Country
- BLK United States
- GILD United States
- Employees
- BLK N/A
- GILD N/A
- Industry
- BLK Investment Bankers/Brokers/Service
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLK Finance
- GILD Health Care
- Exchange
- BLK Nasdaq
- GILD Nasdaq
- Market Cap
- BLK 180.1B
- GILD 147.6B
- IPO Year
- BLK 1999
- GILD 1992
- Fundamental
- Price
- BLK $1,045.76
- GILD $127.67
- Analyst Decision
- BLK Strong Buy
- GILD Buy
- Analyst Count
- BLK 16
- GILD 22
- Target Price
- BLK $1,254.31
- GILD $123.45
- AVG Volume (30 Days)
- BLK 668.6K
- GILD 7.6M
- Earning Date
- BLK 01-14-2026
- GILD 10-30-2025
- Dividend Yield
- BLK 2.00%
- GILD 2.48%
- EPS Growth
- BLK N/A
- GILD 6514.05
- EPS
- BLK 38.83
- GILD 6.42
- Revenue
- BLK $22,885,000,000.00
- GILD $29,087,000,000.00
- Revenue This Year
- BLK $18.66
- GILD $3.05
- Revenue Next Year
- BLK $16.80
- GILD $3.29
- P/E Ratio
- BLK $26.78
- GILD $19.85
- Revenue Growth
- BLK 18.20
- GILD 2.79
- 52 Week Low
- BLK $773.74
- GILD $88.57
- 52 Week High
- BLK $1,219.94
- GILD $128.70
- Technical
- Relative Strength Index (RSI)
- BLK 42.62
- GILD 60.74
- Support Level
- BLK $990.58
- GILD $124.49
- Resistance Level
- BLK $1,032.49
- GILD $128.25
- Average True Range (ATR)
- BLK 22.68
- GILD 3.43
- MACD
- BLK -0.05
- GILD 0.17
- Stochastic Oscillator
- BLK 47.91
- GILD 91.36
About BLK BlackRock Inc.
BlackRock is the largest asset manager in the world, with $13.464 trillion in assets under management at the end of September 2025. Its product mix is diverse, with 55% of managed assets in equity strategies, 24% in fixed income, 9% in multi-asset classes, 7% in money market funds, and 5% in alternatives. Passive strategies account for more than two-thirds of long-term AUM, with the company's ETF platform maintaining a leading market share domestically and on a global basis. Product distribution is weighted more toward institutional clients, which, by our calculations, account for around 80% of AUM. BlackRock is geographically diverse, with clients in more than 100 countries and more than one-third of managed assets coming from investors domiciled outside the US and Canada.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).